Balance Sheet
AssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPrepaid AssetsReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Benitec Biopharma (BNTC) Total Current Liabilities (2019 - 2025)

Benitec Biopharma's Total Current Liabilities history spans 7 years, with the latest figure at $7.0 million for Q1 2025.

  • For Q1 2025, Total Current Liabilities changed N/A year-over-year to $7.0 million; the TTM value through Mar 2025 reached $7.0 million, changed N/A, while the annual FY2024 figure was $4.9 million, 23.78% up from the prior year.
  • Total Current Liabilities for Q1 2025 was $7.0 million at Benitec Biopharma, up from $3.1 million in the prior quarter.
  • Across five years, Total Current Liabilities topped out at $7.0 million in Q1 2025 and bottomed at $1.4 million in Q2 2021.
  • The 5-year median for Total Current Liabilities is $3.0 million (2022), against an average of $3.4 million.
  • The largest annual shift saw Total Current Liabilities skyrocketed 218.36% in 2021 before it crashed 46.24% in 2024.
  • A 5-year view of Total Current Liabilities shows it stood at $2.5 million in 2021, then rose by 0.36% to $2.5 million in 2022, then soared by 130.86% to $5.7 million in 2023, then plummeted by 46.24% to $3.1 million in 2024, then soared by 127.45% to $7.0 million in 2025.
  • Per Business Quant, the three most recent readings for BNTC's Total Current Liabilities are $7.0 million (Q1 2025), $3.1 million (Q4 2024), and $4.6 million (Q3 2024).